Member Info for matarakz

Rapid q16 and q32 are ideal for Care homes, airiports etc with our Versalab- i believe this is mobile lab testing a decentralised laboratory. Very undervalued imo, it won’t be long now we would be above £10.

Westminster trusted WSG and the world should trust WSG. Excellent rns

Imo, in the near future we can apply for FTSE 250. Well done everyone. Novacyt should be at least a billon market cap now.

I stand corrected , imo the contract is more than £500 million. Thanks God??

Is it worth potentially £400-500 million for both phase1and 2?
Well done to all patient investors here.

According to instruction manuals released by Primerdesign, the devices can be operated via a Mac or PC. There is no complex programming or data analysis required. DNA samples obtained via nasal swabs are placed into reaction tubes that are then processed by the machines on-site.
Easier to use. Samples are added into reaction tubes, then machine will process and read the results. NO extraction
Methods needed. This would be a big hit worldwide.

€5 in Paris now!

This is a next level step for Novacyt! We are becoming a mid cap company. Soon we would a billion market cap company and again Patience is the key.

Imo, still overvalued with £1.8 million revenue. As a biotech company- there is no Phase 1 clinical study. This was pumped because because of Covid 19 test which we all knew a very competitive market.

Avacta’s revenue £1.8 million and with a market cap of almost half a billion. FAB is very undervalued imo.

This is a big market for Novacyt. Staffs are tested once a week and residents are tested monthly. There are thousands of care homes in the UK potentially, this would contribute big sales for Novacyt.

Versalab looks like a Mobile laboratory testing! The management team is very competent.

I agreed with your valuation but there is no takeover by AZ. Novacyt is not a speculative buy but is still very undervalued with strong fundamentals. Again there is no takeover or buy out by AZ. Imo

We were able to break the resistance. £5 is coming next week and again we just need patience.

Shorters are being squeezed now. Fundamentals always prevail.

Well done all investors! We r now looking for £5 next week.

Imo, Novacyt is still very undervalued and if I'm not mistaken it is the only Aim company with a projected profit of more than £100 million year end.
No dilutions -No issue of Equities . Majority of Aim companies love issues of equities.
My projected Revenue year end more than £200 millon
Net profit of more than £100 million .
Management team is one of the best in AIM companies.

I believe The company always delivers. The Pathflow lateral test Covid 19 test would be launched before year end. The good thing about this pathflow test is It is not laboratory based test. It xan ve ysed in care homes , airports , gp surgeries etc. £10 is my target .

Vey undervalued imo, Avacta’s market cap is almost half a billion . Technology wise, Fab is much better. Dyor

£4.30 is the resistance. It’s almost in our grasp.
We just need to be patient.